Question 1

What are the potential benefits of participating in this trial compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD clinical trial (NCT06329947). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD clinical trial (NCT06329947). Contact the study team or your healthcare provider for specific answers.

Question 3

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD clinical trial (NCT06329947). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD clinical trial (NCT06329947). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any additional costs or logistical considerations I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD clinical trial (NCT06329947). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my health be monitored throughout the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD clinical trial (NCT06329947). Contact the study team or your healthcare provider for specific answers.

What this study is about